Capivasertib, a potent selective inhibitor of all three AKT isoforms [4], in combination with fulvestrant shows clinical activity in patients with ER+/HER-negative BC, including those with PIK3CA/AKT1/PTEN mutant tumours [11]. This evidence concerns the gene PIK3CA and neoplasm.